Larotaxel

Larotaxel has been used in trials studying the treatment of Cancer, Metastases, Breast Cancer, Breast Neoplasms, and Pancreatic Neoplasms, among others. It is grouped under the following drug class(es): Taxanes. The directory classifies it as a discontinued API with a semi-synthetic source/manufacturing origin. Other names for this substance include larotaxelum, (1S, 2S, 4S, 7R, 8aR, 9aS, 10aR, 12aS, 12bR)-1-(benzoyloxy)-4-(((2R, 3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-2-hydroxy-5, 13, 13-trimethyl-8-oxo-1, 3, 4, 7, 8, 9, 9a, 10, 10a, 12b-decahydro-2H-2, 6-methanocyclodeca[3, 4]cyclopropa[4, 5]benzo[1, 2-b]oxete-7 and 12a(12H)-diyl diacetate. Its PubChem CID is 6918260.

CAS No 156294-36-9
Molecular Formula C45H53NO14
Molecular Weight 831.9 g/mol
Synonyms [(1S,2S,3R,4S,7R,9S,11R,13R,16S)-4,13-diacetyloxy-1-hydroxy-16-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-15,18,18-trimethyl-12-oxo-6-oxapentacyclo[12.3.1.03,11.04,7.09,11]octadec-14-en-2-yl] benzoate

Frequently Asked Questions